Business Wire

ECRON-ACUNOVA

4.12.2015 10:24:06 CET | Business Wire | Press release

Share
Erik Carp appointed Leader Nordic Region at Ecron Acunova A/S, Denmark

Anders Malm, Managing Director of Ecron Acunova and responsible for operations in Europe and North America is pleased to announce that Erik Carp has joined Ecron Acunova as Leader Nordic Region.

Erik Carp joined Ecron Acunova in November with responsibility for the Nordic Region. He will bring much operational experience from local and multinational clinical trials within different therapeutic areas. With a Master in pharmacy from Copenhagen University and a Bachelor in business administration from Copenhagen Business School, Erik Carp brings about 25 years of international clinical operations and business experience from pharmaceutical and biotech companies to Ecron Acunova.

Ecron Acunova (www.ecronacunova.com ) is an expert CRO with over 25 years of track record covering 19 European countries, 9 Asian countries and the United States and Canada. It offers full service clinical research including clinical operations, data management, biostatistics, pharmacovigilance, medical writing, PK/PD services and central laboratory services to pharma, biotech, medical device, nutrition and diagnostic companies. Ecron Acunova operates each region as a priority market with European HQ in Frankfurt, Asian HQ in Singapore, and US HQ in Princeton. With a team of over 350 professionals including about 70 MDs and PhDs, Ecron Acunova is reputed to accelerate pharma time‐to‐market cost effectively.

Speaking on the appointment, Anders Malm, CEO Ecron Acunova Europe, said, “Mr. Carp brings extensive experience in clinical research and he has worked with several CROs over the years as a sponsor. With his experience, Erik Carp can contribute to ensuring that Ecron Acunova’s services continue to meet the specific needs of each our sponsors in terms of quality, timing and budgets. We will continue to serve existing clients and build close relations with biotech and pharmaceutical companies for global as well as local services”.

On his appointment, Mr. Carp said, “Ecron Acunova is a CRO with vast experience within many therapeutic areas. With a highly trained staff in three continents Ecron Acunova has a knowledge base which is unique for a CRO of our size. The company has a global reach, while at the same time we can take care of clients on a local and personal basis. The right size matters in this industry and Ecron Acunova can adapt to the size of each of the sponsors we serve. In our organization, each employee can contribute to the success of our sponsors, make a real difference every day, be visible, accountable and constantly strengthen and develop existing and new competencies. It is a pleasure and privilege for me to be part of Ecron Acunova”.

Contact:

Ecron Acunova Europe HQ
Anders Malm
anders.malm@ecronacunova.com
+49 69 6680 300

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

VerSprite Launches Fork and Knife: AI-Driven Threat Modeling and Adversarial Testing Built for the Speed of Modern Software26.6.2026 23:28:00 CEST | Press release

Powered by the risk-centric PASTA methodology and two decades of accredited offensive security, the integrated platform lets enterprises threat model in a security sprint—then prove the risk through AI-led, human-on-the-loop testing. VerSprite, a global leader in risk-based threat modeling and the firm behind the PASTA (Process for Attack Simulation and Threat Analysis) methodology, today announced the general availability of Fork (www.forktm.com), a continuous application threat modeling platform, alongside Knife, an AI-led, human-on-the-loop adversarial testing platform for web applications and web API endpoints. Together, the two products operationalize a new model for product security—one where applications are securely designed, continuously modeled, and actively tested as part of the build process itself. The launch addresses a problem every security leader knows but few tools have solved: threat modeling is essential, never more so than in an AI-driven era, yet it has remained s

Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 22:30:00 CEST | Press release

Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven

Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse

Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe

Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release

Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye